JYQ-42
| Clinical data | |
|---|---|
| Drug class | Sirtuin-6 (SIRT6) inhibitor |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C13H8ClF3N8O2 |
| Molar mass | 400.71 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
JYQ-42 is a drug which acts as a sirtuin-6 (SIRT6) inhibitor. It has potential applications in cancer treatment, having been found to inhibit the migration of pancreatic cancer cells and thereby reduce tumor invasiveness.[1][2]
References
- ^ Zhang Q, Chen Y, Ni D, Huang Z, Wei J, Feng L, et al. (2022). "Targeting a cryptic allosteric site of SIRT6 with small-molecule inhibitors that inhibit the migration of pancreatic cancer cells". Acta Pharmaceutica Sinica B. 12 (2): 876–889. doi:10.1016/j.apsb.2021.06.015. PMC 8897208. PMID 35256952.
- ^ Chouhan S, Kumar A, Muhammad N, Usmani D, Khan TH (2024). "Sirtuins as Key Regulators in Pancreatic Cancer: Insights into Signaling Mechanisms and Therapeutic Implications". Cancers. 16 (23): 4095. doi:10.3390/cancers16234095. PMC 11640239. PMID 39682281.